Patients HCP
This site is for US residents only.

Results With TAFINLAR + MEKINIST

Proven clinical trial results

In a clinical trial, TAFINLAR + MEKINIST was studied in 2 different groups of people with the BRAF V600E genetic mutation: those taking TAFINLAR + MEKINIST as their first treatment and those previously treated before taking TAFINLAR + MEKINIST. 

TAFINLAR + MEKINIST is a proven choice for patients with BRAF V600E metastatic NSCLC

Slows or shrinks tumors

In a clinical trial, TAFINLAR + MEKINIST was shown to help shrink or slow the growth of tumors in previously untreated and previously treated patients.

Overall response rate

  • The overall response rate measures the size or number of tumors people have. This number includes:

    • people whose tumors became smaller or fewer in number (which is called a partial response), and

    •  people whose tumors disappeared completely (which is called a complete response); a complete response is not the same thing as a cure

For those taking TAFINLAR + MEKINIST as their first treatment

61% of 36 untreated patients achieved a response with TAFINLAR + MEKINIST

A total of 61% of 36 untreated patients achieved a response with TAFINLAR + MEKINIST. A total of 8% of untreated patients had a complete response and 53% had a partial response. 
 


For those previously treated before taking TAFINLAR + MEKINIST

61% of 57 previously treated patients achieved a response with TAFINLAR + MEKINIST

A total of 61% of 57 previously treated patients achieved a response with TAFINLAR + MEKINIST. Of these responders, 5% had a complete response and 56% of patients had a partial response. 

Duration of response

  • Duration of response is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading

 

For those taking TAFINLAR + MEKINIST as their first treatment

Median duration of response for patients never treated was 15.2 months

The median (or midpoint) duration of response for patients who have never been treated was 15.2 months. That means that half of the patients who responded to treatment continued to respond longer than 15.2 months and half responded for less than 15.2 months.

 

For those previously treated before taking TAFINLAR + MEKINIST

Median duration of response for patients previously treated was 9 months

The median (or midpoint) duration of response for patients who were previously treated was 9 months. That means that half of the patients who responded to treatment continued to respond longer than 9 months and half responded for less than 9 months.